OBLN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OBLN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Obalon Therapeutics has the Profitability Rank of 0.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Obalon Therapeutics's Operating Margin % for the quarter that ended in Mar. 2021 was %. As of today, Obalon Therapeutics's Piotroski F-Score is 0.
For the Medical Devices subindustry, Obalon Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Obalon Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Obalon Therapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Obalon Therapeutics has the Profitability Rank of 0.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Obalon Therapeutics's Operating Margin % for the quarter that ended in Mar. 2021 is calculated as:
Operating Margin % | = | Operating Income (Q: Mar. 2021 ) | / | Revenue (Q: Mar. 2021 ) |
= | -4.168 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Obalon Therapeutics has an F-score of 0. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Obalon Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Raymond V Dittamore | director | P O BOX 2050, GLENWOOD SPRINGS CO 81602 |
William J. Plovanic | director | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008 |
Sharon Stevenson | director | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ECINAS, SUITE F, CARLSBAD CA 92008 |
Douglas Fisher | director | 587 PATROL RD, WOODSIDE CA 94062 |
Lesley H Howe | director | |
Kim P. Kamdar | director | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Andrew P Rasdal | director, officer: President, CEO & Exec Chairman | C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121 |
Nooshin Hussainy | officer: Chief Financial Officer | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008 |
Mark Brister | officer: Chief Technology Officer | C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121 |
Robert J Macdonald | officer: Chief Retail Officer | C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008 |
Amy Vandenberg | officer: Chief Clinical & Reg Officer | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008 |
Nicole Vitullo | 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Brian H Dovey | 10 percent owner | ONE PALMER SQUARE, PRINCETON NJ 08542 |
Arnold L Oronsky | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
Gilbert H Kliman | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
From GuruFocus
By [email protected] insider • 11-14-2019
By [email protected] insider • 07-23-2020
By PRNewswire PRNewswire • 01-21-2021
By PRNewswire PRNewswire • 12-10-2019
By Marketwired Marketwired • 03-18-2020
By Marketwired Marketwired • 02-08-2020
By GlobeNewswire GlobeNewswire • 11-05-2019
By ACCESSWIRE ACCESSWIRE • 05-21-2021
By Marketwired Marketwired • 11-05-2019
By Business Wire Business Wire • 01-22-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.